Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show

When Alnylam scored an FDA approval for its second RNAi therapy, Givlaari, late last year, some market watchers cast a wary eye on the drug's short stay in the clinic and questionable safety profile. But after eight months on the market, Alnylam is touting longer-term, open-label data for Givlaari that could put some of those worries to rest.